Recordati SpA  

(Public, BIT:REC)   Watch this stock  
Find more results for REC
31.60
-0.50 (-1.56%)
Real-time:   2:06PM GMT+2
BIT real-time data - Disclaimer
Currency in EUR
Range 31.04 - 31.71
52 week 21.27 - 31.92
Open 31.49
Vol / Avg. 521,851.00/494,778.00
Mkt cap 6.61B
P/E 27.84
Div/yield 0.35/2.22
EPS 1.14
Shares 205.23M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 18.90% 20.58%
Operating margin 25.73% 28.37%
EBITD margin - 32.76%
Return on average assets 13.91% 15.67%
Return on average equity 23.37% 26.77%
Employees 4,116 -
CDP Score - -

Address

Via M. Civitali, 1
MILANO, 20148
Italy
+39-02-487871 (Phone)
+39-02-40073747 (Fax)

Website links

Description

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA and Pro Farma AG.

Officers and directors

Alberto Recordati Chairman
Andrea Recordati Chief Executive Officer, Vice Chairman
Fritz Squindo Chief Financial Officer, Financial Reporting Officer, General Manager for the Coordination of Group Operations, Executive Director
Roberto Teruzzi Executive Vice President of Group Industrial Operations
Luisa Mainoli Vice President and Director Group Finance
Giuseppe Gualazzini Vice President and Director Group Human Resources
Age: 58
Luca Bolliger Vice President and Director of Corporate Licensing
Corrado Castellucci Vice President and Director Orphan Drugs
Gabriele Finzi Vice President and Director Corporate Development
Daria Ghidoni Vice President and Director Corporate Legal Affairs